T2 Biosystems announced the presentation of data strongly correlating T2Hemostat results with patients’ clinical outcomes. In 26 patients who presented with chest pain and underwent cardiac catheterization, T2HemoStat was compared to a common platelet activity assay, where T2HemoStat accurately correlated to 100 percent of bleeding event cases while the comparator did not identify bleeding events in any patients. T2HemoStat also correlated to twice the number of thrombotic cases than the comparator. These data are complemented by additional presentations that demonstrate T2MR’s ability to identify novel clot biology, which may account for previously unexplained clot behavior while providing new clinical insights into the formation and degradation of blood clots. T2HemoStat is the company’s novel system for the rapid detection of physical changes in a blood sample, identifying novel clot biology while also measuring hemostasis characteristics such as coagulation, fibrinolysis and platelet function from finger stick size, small volumes of whole blood or plasma on a single, compact instrument.

Itamar-Medical announced that the American Medical Association (AMA) has awarded a Current Procedure Terminology (CPT) Category III reimbursement code to a test performed by its EndoPAT proprietary device.

July 18, 2013 — Two reports from AmericanEHR Partners, based on a survey of nearly 1,400 physicians, suggest that tablets are of greater use for clinical purposes than smart phones.

Shore University Medical Center is one of only a handful of hospitals in the country offering the recent U.S. Food and Drug Administration (FDA)-approved Lariat Suture Delivery Device procedure. Electrophysiologists and interventional cardiologists perform this innovative procedure to help prevent stroke in patients who suffer from atrial fibrillation and are unable to take blood thinners.